BioCentury | Mar 9, 2019
Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

...Van Vlasselaer as independent executive chairman. Smith is a veteran of Gilead Sciences Inc. (NASDAQ:GILD), Arresto Biosciences Inc....
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...Inc. Spleen tyrosine kinase (SYK) inhibitors Preclin Autoimmune disease 2010 Up to $120M Ph II Arresto BioSciences Inc....
BioCentury | Jan 6, 2016
Clinical News

Gilead terminates simtuzumab IPF study

...against lysyl oxidase-like 2 ( LOXL2 ). Gilead gained the candidate via its acquisition of Arresto BioSciences Inc....
BioCentury | Sep 22, 2014
Clinical News

Simtuzumab: Phase II data

...non-alcoholic steatohepatitis (NASH) are expected in mid-2015. Gilead gained simtuzumab through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Sep 18, 2014
Clinical News

Gilead's simtuzumab misses in pancreatic cancer

...simtuzumab, a humanized mAb against lysyl oxidase-like 2 (LOXL2) , through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Sep 8, 2014
Strategy

Parsing Roche's IPF bet

...lysyl oxidasle-like 2 ( LOXL2 ) that the company gained through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Nov 25, 2013
Emerging Company Profile

Armo: Reviving IL-10

...see BioCentury, Oct. 2, 2006). He was subsequently founding CEO of cancer and inflammation company Arresto BioSciences Inc....
BioCentury | May 28, 2012
Finance

AbbVie earlier

...and a half years ago. The firm has had one exit: the 2010 acquisition of Arresto BioSciences Inc....
BioCentury | Feb 13, 2012
Clinical News

GS-6624: Phase II started

...progressed after first-line oxaliplatin- and fluoropyrimidine-containing regimen. Gilead acquired GS-6624 through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Feb 13, 2012
Clinical News

GS-6624: Phase II started

...about 244 patients with metastatic pancreatic adenocarcinoma. Gilead acquired GS-6624 through its 2011 acquisition of Arresto BioSciences Inc....
Items per page:
1 - 10 of 33
BioCentury | Mar 9, 2019
Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

...Van Vlasselaer as independent executive chairman. Smith is a veteran of Gilead Sciences Inc. (NASDAQ:GILD), Arresto Biosciences Inc....
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...Inc. Spleen tyrosine kinase (SYK) inhibitors Preclin Autoimmune disease 2010 Up to $120M Ph II Arresto BioSciences Inc....
BioCentury | Jan 6, 2016
Clinical News

Gilead terminates simtuzumab IPF study

...against lysyl oxidase-like 2 ( LOXL2 ). Gilead gained the candidate via its acquisition of Arresto BioSciences Inc....
BioCentury | Sep 22, 2014
Clinical News

Simtuzumab: Phase II data

...non-alcoholic steatohepatitis (NASH) are expected in mid-2015. Gilead gained simtuzumab through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Sep 18, 2014
Clinical News

Gilead's simtuzumab misses in pancreatic cancer

...simtuzumab, a humanized mAb against lysyl oxidase-like 2 (LOXL2) , through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Sep 8, 2014
Strategy

Parsing Roche's IPF bet

...lysyl oxidasle-like 2 ( LOXL2 ) that the company gained through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Nov 25, 2013
Emerging Company Profile

Armo: Reviving IL-10

...see BioCentury, Oct. 2, 2006). He was subsequently founding CEO of cancer and inflammation company Arresto BioSciences Inc....
BioCentury | May 28, 2012
Finance

AbbVie earlier

...and a half years ago. The firm has had one exit: the 2010 acquisition of Arresto BioSciences Inc....
BioCentury | Feb 13, 2012
Clinical News

GS-6624: Phase II started

...progressed after first-line oxaliplatin- and fluoropyrimidine-containing regimen. Gilead acquired GS-6624 through its 2011 acquisition of Arresto BioSciences Inc....
BioCentury | Feb 13, 2012
Clinical News

GS-6624: Phase II started

...about 244 patients with metastatic pancreatic adenocarcinoma. Gilead acquired GS-6624 through its 2011 acquisition of Arresto BioSciences Inc....
Items per page:
1 - 10 of 33